Brief: Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation For Rencofilstat For The Treatment Of Hepatocellular Carcinoma
20/06/2022 13:53
June 20 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG STATUS
DESIGNATION FOR RENCOFILSTAT FOR THE TREATMENT OF HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nGNX6yFbFy
Further company coverage: HEPA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement